Supplementary Figure 1

3
Supplementary Figure 1 0 (negative ) 1 (weak) 2 (moderate) 3 (strong) E F G H 1 (1 25%) 2 (26 50%) 3 (51 75%) 4 (76 100%) A B C D

description

Supplementary Figure 1. D. B. A. C. 3 (51 ~ 75%). 2 (26 ~ 50%). 1 (1 ~ 25%). 4 (76 ~ 100%). E. F. G. H. 3 (strong). 2 (moderate). 0 (negative). 1 (weak). Supplementary Figure 2. A. SW480. HT29. C. D. ANGPTL2/GAPDH. ANGPTL2/GAPDH. ANGPTL2/GAPDH. E. B. F. SW480. HT29. - PowerPoint PPT Presentation

Transcript of Supplementary Figure 1

Page 1: Supplementary Figure  1

Supplementary Figure 1

0 (negative) 1 (weak) 2 (moderate) 3 (strong)

E F G H

1 (1 ~ 25%) 2 (26 ~ 50%) 3 (51 ~ 75%) 4 (76 ~ 100%)

A B C D

Page 2: Supplementary Figure  1

si negative si ANGPTL2 0

1

2

3

4

5

6

AN

GPTL2

/GA

PD

H

CA

Caco2 DLD1 HT29 Lovo SW4800

2

4

6

8

10

12

14

16

18

AN

GPTL2

/GA

PD

H

si negative si ANGPTL2 0

0.5

1

1.5

2

2.5

3

3.5

4

AN

GPTL2

/GA

PD

H

D

si negative si ANGPTL20

0.20.40.60.8

11.21.41.61.8

2

AN

GPTL2

(O

D)

E

AN

GPTL2

(O

D)

Caco2 DLD1 HT29 Lovo SW4800.45

0.50.55

0.60.65

0.70.75

0.80.85

0.9

B

si negative si ANGPTL20

0.5

1

1.5

2

2.5

AN

GPTL2

(O

D)

F

SW480

SW480

HT29

HT29

Supplementary Figure 2

Page 3: Supplementary Figure  1

Supplementary Figure 3

0 20 40 60 80 1000

20

40

60

80

100

100-Specificity

Sen

sitiv

ity

AUC = 0.859

CRC patients with CEA <5A

0 20 40 60 80 100

0

20

40

60

80

100

100-SpecificityS

ensi

tivity

Stage I CRC patients with CEA <5

AUC = 0.804

B